Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $3.00 target price on the stock.

Other analysts have also recently issued research reports about the company. HC Wainwright cut their target price on Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday. Guggenheim restated a “buy” rating and set a $12.00 target price on shares of Outlook Therapeutics in a research report on Friday, January 17th. Finally, BTIG Research dropped their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Outlook Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Outlook Therapeutics Trading Down 8.6 %

OTLK opened at $1.71 on Tuesday. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The company has a market cap of $54.69 million, a price-to-earnings ratio of -0.19 and a beta of 0.58. The company’s 50 day moving average is $1.88 and its 200 day moving average is $4.41.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, February 14th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.04). As a group, analysts predict that Outlook Therapeutics will post -2.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC grew its holdings in Outlook Therapeutics by 133.9% during the 4th quarter. Jane Street Group LLC now owns 26,218 shares of the company’s stock worth $50,000 after acquiring an additional 15,008 shares in the last quarter. Scotia Capital Inc. boosted its holdings in Outlook Therapeutics by 124.4% in the fourth quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock worth $140,000 after acquiring an additional 41,023 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Outlook Therapeutics during the fourth quarter worth $246,000. Russell Investments Group Ltd. increased its holdings in shares of Outlook Therapeutics by 34,936.7% in the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock valued at $32,000 after purchasing an additional 17,119 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in Outlook Therapeutics during the 4th quarter valued at approximately $48,000. 11.20% of the stock is currently owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.